incretin mimetic comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
=== PIP1 and PIP2 === The 3-D structures of the open and closed forms of plant aquaporins, PIP1 and PIP2, have been solved (PDB: 4JC6). In the closed conformation, loop D caps the channel from the cytoplasm and thereby occludes the pore. In the open conformation, loop D is displaced up to 16 Å, and this movement opens a hydrophobic gate blocking the channel entrance from the cytoplasm. These results reveal a molecular gating mechanism which appears conserved throughout all plant plasma membrane aquaporins. In plants it regulates water intake/export in response to water availability and cytoplasmic pH during anoxia.
Mendelevium was the ninth transuranic element to be synthesized. It was first synthesized by Albert Ghiorso, Glenn T. Seaborg, Gregory Robert Choppin, Bernard G. Harvey, and team leader Stanley G. Thompson in early 1955 at the University of California, Berkeley. The team produced 256Md (half-life 77.7 minutes) when they bombarded an 253Es target consisting of only a billion (109) einsteinium atoms with alpha particles (helium nuclei) in the Berkeley Radiation Laboratory's 60-inch cyclotron, thus increasing the target's atomic number by two. 256Md thus became the first isotope of any element to be synthesized one atom at a time. In total, seventeen mendelevium atoms were detected. This discovery was part of a program, begun in 1952, that irradiated plutonium with neutrons to transmute it into heavier actinides. This method was necessary because of a lack of known beta decaying isotopes of fermium that might allow production by neutron capture; it is now known that such production is impossible at any possible reactor flux due to the very short half-life to spontaneous fission of 258Fm and subsequent isotopes, which still do not beta decay - the fermium gap that, as far as we know, sets a hard limit to the success of neutron capture processes.
Ralph William James Rimmer. Lately Chief Executive Officer, Rugby Football League. For services to Rugby League Football. Dr. Lisa Margaret Ritchie. Head of Infection Prevention and Control, NHS England. For services to Healthcare, particularly during Covid-19. Michael Thomas Robinson. Chief Executive, Royal Scottish Geographical Society. For services to Climate Change Education. Professor Colva Mary Roney-Dougal. Professor of Mathematics, University of St Andrews. For services to Education and Mathematics. Kenneth James Gordon Harvey Ross. Founding Officer, National Down Syndrome Policy Group. For services to Charity, to Education and to People with Down Syndrome. Diane Rosalie Aldworth Ruddock. For services to the Environment, to Heritage and to the community in Northern Ireland. John Hamilton Ryley. Lately Head of News, Sky News. For services to Journalism. Clovis Constantine Salmon. Documentary Filmmaker. For services to Culture and to the Black Community. William Henry Salomon. President, Young Enterprise. For services to Education. Carolyn Margaret Sampson. Soprano. For services to Music. Steven Ross Savory. Chief Executive Officer, Gloucestershire Learning Alliance. For services to Education. Professor Ulrike Hermine Schmidt. Professor of Eating Disorders, King's College London and Consultant Psychiatrist, South London and Maudsley NHS Foundation Trust. For services to People with Eating Disorders. Ian Charles Sears. Commercial Specialist, Cabinet Office. For Public Service. Ruth Victoria Shaw. Chief Executive Officer, Premier League Charitable Fund.
Immuno-ligation methods High-throughput multiplex assays allow for the simultaneous detection of multiple proteins and thus improve profiling capabilities. This is opening up avenues to even more clinical applications with increased precision and biology.
=== India === In the 1990s, India stopped its research in cold fusion at the Bhabha Atomic Research Centre because of the lack of consensus among mainstream scientists and the US denunciation of the research. Yet, in 2008, the National Institute of Advanced Studies recommended that the Indian government revive this research. Projects were commenced at Chennai's Indian Institute of Technology, the Bhabha Atomic Research Centre and the Indira Gandhi Centre for Atomic Research. However, there is still skepticism among scientists and, for all practical purposes, research has stalled since the 1990s. A special section in the Indian multidisciplinary journal Current Science published 33 cold fusion papers in 2015 by major cold fusion researchers including several Indian researchers. A Hyderabad-based startup, Hylenr Technologies, showcased the amplification of electrical energy into significantly more heat energy using the a LENR system. The startup is being guided by a former DRDO scientist, Padma Shri awardee, Dr. Prahlada Ramarao.
Sources: en.wikipedia.org
A human chimera is a human with a subset of cells with a distinct genotype than other cells, that is, having genetic chimerism. An organism that contains a mixture of human and non-human cells would be a human–animal chimera.
== History == EARS-Net is the collaborative effort of 29 countries. The information documented are antibiotic resistance which are determined according to the EUCAST standard. Around 80% of the participants utilize the EUCAST standard for detection of antibiotic resistance. EARS-Net was established in 1998 as EARSS, funded by the European Commission's Directorate General for Health and Consumer Affairs and the Dutch Ministry of Health, Welfare and Sports. However, in January 2010, it was transferred to the European Centre for Disease Prevention and Control (ECDC) where it was renamed EARS-Net.
The ambient temperature 1H NMR spectrum shows two methyl signals, indicative of hindered rotation about the (O)C−N bond. At temperatures near 100 °C, the 500 MHz NMR spectrum of this compound shows only one signal for the methyl groups. DMF is miscible with water. The vapour pressure at 20 °C is 3.5 hPa. A Henry's law constant of 7.47 × 10−5 hPa·m3/mol can be deduced from an experimentally determined equilibrium constant at 25 °C. The partition coefficient log POW is measured to −0.85. Since the density of DMF (0.95 g·cm−3 at 20 °C) is similar to that of water, significant flotation or stratification in surface waters in case of accidental losses is not expected.
The Bradford protein assay (also known as the Coomassie protein assay) was developed by Marion M. Bradford in 1976. It is a quick and accurate spectroscopic analytical procedure used to measure the concentration of protein in a solution. The reaction is dependent on the amino acid composition of the measured proteins. The original paper presenting and revealing the Bradford protein assay is one of the most cited academic papers in history, currently ranking 3rd on the all-time citation list with just over 150,000 citations.
=== Pharmacokinetics === Hydroxyzine can be administered orally or via intramuscular injection. In both cases it is rapidly absorbed and distributed. It is metabolized in the liver and the main metabolite (45%), cetirizine is formed through oxidation of the alcohol moiety to a carboxylic acid by alcohol dehydrogenase. Overall effects are observed within one hour of administration. Higher concentrations are found in the skin than in the plasma. Cetirizine, although less sedating, is non-dialyzable and possesses similar antihistamine properties. Metabolites identified include an N-dealkylated metabolite and an O-dealkylated 1/16 metabolite with a plasma half-life of 59 hours. These pathways are mediated principally by CYP3A4 and CYP3A5. The N-dealykylated metabolite, norchlorcyclizine, bears some structural similarities to trazodone, but it has not been established whether it is pharmacologically active. In animals, hydroxyzine and its metabolites are excreted in feces primarily through biliary elimination. In rats, less than 2% of the drug is excreted unchanged. The time to reach maximum concentration (Tmax) of hydroxyzine is about 2.0 hours in both adults and children and its elimination half-life is around 20.0 hours in adults (mean age 29.3 years) and 7.1 hours in children. Its elimination half-life is shorter in children compared to adults. In another study, the elimination half-life of hydroxyzine in elderly adults was 29.3 hours.
Sources: en.wikipedia.org
=== Risk to the social safety net === CBO estimates OBBBA would cause 10.9 million Americans to lose health insurance coverage. Other estimates of this figure said it would strip nearly nine million people of their coverage, leaving between 10.3 million to 14 million people uninsured. The bill's cuts to Medicaid were the largest in the program's history and put rural hospitals at risk of closure with one clinic attributing their announced closure to the bill. The loss of coverage for millions of Americans is expected to strain the finances of hospitals, nursing homes, and community health centers, which will be left to absorb more of the cost of treating the uninsured. Further CBO analysis released August 11, 2025, estimated that the highest 10% of earners would see incomes rise by 2.7% by 2034 mainly due to tax cuts, while the lowest 10% would see incomes fall by 3.1% mainly due to cuts to programs such as Medicaid and food aid. Analysis of the bill by the CBO and multiple think tanks found it to be one of the most regressive bills in decades. The Center for a Responsible Federal Budget estimates that the bill will accelerate the estimated insolvency of Social Security and Medicare by one year. Experts have argued that the bill would create the largest upward transfer of wealth from the poor to the rich in American history due to large-scale benefit cuts paired with tax breaks for high-income earners and corporations.
== Casting == Kipa-Williams was cast as Ari having given up acting in the wake of the cancellation of 800 Words, in which he played a recurring role. He had also suffered disappointment at missing out on several roles, which often occurred when he reached the final two at the casting stage. Kipa-Williams wanted "some stability", so he began considering things like family, buying a house, and training for a new career as an insurance adviser. When he was given the character brief for Ari, he was unsure about returning to acting, but he felt like the character was "a really strong fit" for him and he attended the audition. After being offered the role, he realised that it meant he would have to relocate from New Zealand to Sydney. He admitted that he was happy he went through with the move, as the show helped him regain his love of acting. Kipa-Williams signed a three-year contract, and he began filming around six months before his debut in the 2019 season finale. His appearance confirmed speculation that a new family was joining the cast of Home and Away, following the departures of three members of the Morgan family.
Many mammalian species have developed keratinized penile spines along the glans or shaft, which may be involved in sexual selection. These spines have been described as being simple, single-pointed structures (macaques) or complex with two or three points per spine (strepsirrhines). Penile spine morphology may be related to mating system.
==== Eastern copperhead ==== The eastern copperhead (Agkistrodon contortrix) is a species of venomous snake, a pit viper, endemic to eastern North America; it is a member of the subfamily Crotalinae in the family Viperidae. The generic name is derived from the Greek words ancistro (hooked) and odon (tooth), and the specific name comes from the Latin contortus (twisted, intricate, complex); thus, the scientific name translates into "twisted hook-tooth".
The Labor Management Relations Act, 1947, better known as the Taft–Hartley Act, is a United States federal law that restricts the activities and power of labor unions. It was enacted by the 80th United States Congress over the veto of President Harry S. Truman, becoming law on June 23, 1947. The Taft–Hartley Act was introduced in the aftermath of a major strike wave in 1945 and 1946. Though it was enacted by the Republican-controlled 80th Congress, the law received significant support from congressional Democrats, many of whom joined with their Republican colleagues in voting to override Truman's veto. The act continued to generate opposition after Truman left office, but it remains in effect. The Taft–Hartley Act amended the 1935 National Labor Relations Act (NLRA), adding new restrictions on union actions and designating new union-specific unfair labor practices. Among the practices prohibited by the Taft–Hartley act are jurisdictional strikes, wildcat strikes, solidarity or political strikes, secondary boycotts, secondary and mass picketing, closed shops, and monetary donations by unions to federal political campaigns. The amendments also allowed states to enact right-to-work laws banning union shops. Enacted during the early stages of the Cold War, the law required union officers to sign non-communist affidavits with the government.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.